key: cord-0918200-n3st2ubz
authors: Luft, Thomas; Dreger, Peter; Radujkovic, Aleksandar
title: Endothelial cell dysfunction: a key determinant for the outcome of allogeneic stem cell transplantation
date: 2021-07-12
journal: Bone Marrow Transplant
DOI: 10.1038/s41409-021-01390-y
sha: 3bd8246776ea12714f2b8432a4787a21d3e0fdef
doc_id: 918200
cord_uid: n3st2ubz

Allogeneic hematopoietic stem cell transplantation (alloSCT) carries the promise of cure for many malignant and non-malignant diseases of the lympho-hematopoietic system. Although outcome has improved considerably since the pioneering Seattle achievements more than 5 decades ago, non-relapse mortality (NRM) remains a major burden of alloSCT. There is increasing evidence that endothelial dysfunction is involved in many of the life-threatening complications of alloSCT, such as sinusoidal obstruction syndrome/venoocclusive disease, transplant-associated thrombotic microangiopathy, and refractory acute graft-versus host disease. This review delineates the role of the endothelium in severe complications after alloSCT and describes the current status of search for biomarkers predicting endothelial complications, including markers of endothelial vulnerability and markers of endothelial injury. Finally, implications of our current understanding of transplant-associated endothelial pathology for prevention and management of complications after alloSCT are discussed.

The endothelium is a semipermeable monolayer of endothelial cells (EC) organized as a complex biological interface that separates all tissues from circulating blood. The vascular endothelium is a highly active organ involved in the regulation of the vascular tone, cellular adhesion and migration, coagulation, vessel wall permeability, and various inflammatory processes [1, 2] . In the setting of alloSCT, host ECs may also participate in adaptive immune responses [3] .

During alloSCT, ECs are consecutively challenged by toxicities of the conditioning regimen and the drugs used for immunosuppressive prophylaxis, inflammatory molecules released by damaged cells and tissues, endotoxins due to damaged mucosal barriers, donor leukocyte engraftment, and alloreactive immune responses [3] . Individual responses of patients' ECs may be driven by both acquired endothelial distress (caused by comorbidities, pretreatment toxicity, etc.) and an intrinsic endothelial vulnerability (e.g. genetic polymorphisms [4] ) (Fig. 1 ). Possible consequences are EC activation and injury that may progress to an irreversible state of endothelial dysfunction. In turn, a proinflammatory, pro-coagulant and pro-apoptotic process is triggered, manifesting as endothelial injury syndromes. Here we focus on the most prominent of them, namely sinusoidal obstruction syndrome/venoocclusive disease (SOS/VOD), transplantassociated thrombotic microangiopathy (TA-TMA), and refractory acute GVHD. Additional endothelial injury syndromes after alloSCT not addressed in this overview include i.a. vascular type idiopathic pneumonia syndrome [5] , early fluid retention [6] , early bilirubinaemia [7] posterior reversible encephalopathy syndrome, and several subtypes of chronic GVHD [8] .

For delineating the pathogenesis, but also for diagnosis and prediction of the main endothelial injury syndromes VOD/SOS, TA-TMA, and refractory acute graft-versus host disease (GVHD), extensive efforts have been made to identify biomarkers of endothelial damage and dysfunction.

VOD/SOS manifests as damage of sinusoidal ECs, resulting in the liver injury of various degrees. It is characterized by rapid weight gain, ascites, painful hepatomegaly, and jaundice [9, 10] . Several groups have focused on VOD/SOS-related endothelial biomarkers as summarized in Table 1 [11] [12] [13] [14] [15] [16] .

TA-TMA is another endothelial syndrome associated with excess mortality in the early post-transplant period. TA-TMA may affect up to 25-30% allografted patients with up to 90% mortality rates in its most severe forms [17] . TA-TMA is characterized by the endothelial injury resulting in microangiopathic hemolytic anemia, platelet consumption, complement dysregulation, and thrombosis and fibrin deposition in the microcirculation [18] .

Endothelial biomarkers for diagnosis or prognostication of TA-TMA are summarized in Table 1 [19] [20] [21] [22] [23] [24] [25] [26] [27] . Algorithms were proposed to identify high-risk patients most likely benefitting from targeted treatment interventions such as terminal complement blockade (Table 1) . Inamoto et al. [28] introduced the concept of intestinal transplant-associated microangiopathy as a separate entity observed in patients with severe steroid-refractory diarrhea not meeting the clinical criteria of systemic TMA or GVHD.

Acute GVHD (aGVHD) is the most critical complication following alloSCT, in particular its steroid-refractory form, and represents one of the major causes of mortality. Its complex pathophysiology involves cytokine dysregulation and sequential activation of T cells and monocytes [29] . Upon damage by the early toxicities (conditioning, calcineurin inhibitors (CNI), donor leukocyte engraftment), the endothelium itself may also become a target for activated allogeneic T cells at the onset of aGVHD [3] .

First histological evidence of immunologic vascular injury was retrieved from skin biopsies of patients suffering from cutaneous aGVHD, showing perivascular VWF deposition. In addition, loss of endothelial TM, increased expression of ICAM-1 and VCAM-1, and extravasation of vWF was observed in tissue specimens of patients with aGVHD, pointing to EC involvement (Table 1 [ [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] ).

Another blood-derived endothelial biomarker considered for aGVHD is ANG2, both as a single marker [35, 48] and as part of a biomarker panel [46] . ANG2 was shown to be predictive for general endothelial damage-related transplant complications, and particularly for the development of treatment-refractory aGVHD (Table 1) . Additional endothelial markers are summarized in Table 1 .

Finally, ST2 has become an important focus of biomarker research for aGVHD prediction and prognostication [36, 40, 47, 49] . This marker also associates with TA-TMA [24, 27] and thus underlines the link between microangiopathy and lethal complications (Table 1) .

Functional heterogeneity is a hallmark of the endothelial cell system [50, 51] . The hypothetical functional definition of ECs as input-output devices [50, 52] emphasizes their role as direct responders to a variety of challenges such as blood pressure, temperature, pH and oxygen pressure, and serum factors [51, 53] . Maintaining homeostasis of tissue perfusion is an important function of ECs that are continuously exposed to stimuli provided by the alternative complement pathway, coagulation factors, cytokines, activated platelets, leukocytes, and occasional infectious agents. Due to their distribution over space and time, hardly two ECs will be exposed to the same set of input signals [54] . Moreover, stochastic or inheritable heterogeneous DNA methylation patterns add to the functional variability of seemingly "homogeneous" mature EC populations [55, 56] . Therefore, tissue-specific stress responses of ECs can explain that even during systemic EC dysfunction (e.g. due to CNI, viruses, irradiation etc.), microangiopathy develops locally in individual patients [54] .

This functional heterogeneity has to be considered in all attempts to define clinical diagnostic criteria for endothelial complications after alloSCT. It also explains the difficulties in defining unequivocal diagnostic criteria for TA-TMA and VOD/ SOS. E.g. for TA-TMA, based on expert opinion rather than biology, diverse consensus-defined cut-offs for creatinine, lactate dehydrogenase (LDH), platelet and schistocyte counts, weight gain, and bilirubin levels exist, resulting in discordant diagnostic systems with strongly diverging prognostic impact [20, [57] [58] [59] .

Ideal markers should be capable of predicting endothelial dysfunction in different clinical settings. Not surprisingly, many endothelial biomarkers described in alloSCT, e.g. ST2 [60] , ANG2 [61, 62] , ADMA [63] , Nitrates [64] , TM [65] , and others, also predict outcome in cardiovascular disorders. However, these markers were developed generally for diagnosis and/or prognostication of manifest clinical problems rather than for predicting systemic endothelial dysfunction as defined above.

In contrast, the goal should be to find biomarkers indicating an increased endothelial risk even before the onset of endothelial complications, ideally before transplant. This risk could consist in a pre-existing subclinical or clinical endothelial defect conferring a generally increased likelihood of endothelial complications and mortality: endothelial injury. Alternatively, the risk could consist in the predisposition of an otherwise intact endothelium of becoming dysfunctional only after a triggering event such as GVHD or other second hits: endothelial vulnerability (Fig. 1) .

In contrast to the immune system, which is usually completely replaced by cells of donor origin after alloSCT, ECs remain exclusively recipient-derived. This implies that pre-existing defects may impair post-transplant homeostasis of the endothelium and its capacity of enduring eventual challenges, such as the aforementioned noxae, but also the interaction between recipient ECs and donor immune cells and platelets.

The concept of endothelial vulnerability is based on the observation that serum markers of endothelial cell distress such as nitrates, ANG2, and ADMA, when elevated before conditioning therapy, are associated with increased NRM only in case of a second hit, namely aGVHD, but not in patients who do not develop aGVHD [32, 35] . Similarly, defined single nucleotide polymorphisms in recipient genes related to endothelial integrity, such as the TM and CD40Ligand genes, result in a significantly poorer outcome of patients with aGVHD, without affecting survival in the absence of GVHD [4, 66] (Table 2) . This resembles other endothelial complications outside the transplant setting, such as atypical hemolytic-uremic syndromes (aHUS), that are based on pathogenic alterations in various components of the complement pathway but require additional challenges before actual endothelial cell dysfunction occurs [67] . This 2-step model of endothelial vulnerability is also supported by the observation that only a minority of patients with gastrointestinal GVHD shows loss of endothelial surface expression of TM as a sign of endothelial damage at disease onset, although serum CD141 levels subsequently increase in most refractory patients [31, 35] . This supports the view that preexisting endothelial vulnerability paves the way for a progressive microangiopathy developing under the stress posed by aGVHD, adding to organ damage and finally resulting in steroid refractoriness (Fig. 2 ) [35] . The lack of predictive power in patients without aGVHD is a strong hint that endothelial vulnerability markers do not reflect manifest endothelial damage. In contrast, endothelial markers measured pre-transplant or early post-transplant which are associated with an increased risk of NRM (or TMA as the common clinical end stage of endothelial damage) independent of GVHD can be considered as indicators of an actually injured endothelium associated with already manifest endothelial dysfunction. Examples for this type of markers are ST2 and IL18 [27, 68] (Fig. 1/Fig. 2 / Table 2) .

Because the triad of increased creatinine and LDH together with low platelet counts represents the cornerstone of TA-TMA diagnosis, we explored if the ratio of LDH*creatinine/platelets as a continuous, quantitative read-out, termed "Endothelial activation and Stress Index" or EASIX, could serve as easy-to-assess surrogate for measuring endothelial injury. Indeed, EASIX measured pre-transplant (EASIX-pre) predicts TA-TMA and NRM, EASIX measured on day 0 of transplantation (EASIX-d0) predicts SOS/ VOD, and EASIX measured at the onset of acute GVHD (EASIX-aGVHD) predicts NRM [69] [70] [71] [72] . In addition, EASIX-pre and EASIX-d0 correlate with newly recognized syndromes of endothelial cell dysfunction such as early fluid retention [6] and early hyperbilirubinaemia (irrespective of SOS/VOD) [7] .

Similar to established endothelial dysfunction markers, EASIXpre predicts outcome also in patients without aGVHD [71, 72] . Accordingly, EASIX-pre correlates with markers of endothelial injuries, such as IL18, and low IGF1, but not with vulnerability markers [71] (Table 2 ). In conclusion, EASIX is a readily available indicator of actual endothelial dysfunction throughout the whole peritransplant period. Its applicability in non-transplant clinical settings, such as prognostication of lower risk myelodysplastic syndromes [73] , multiple myeloma [74] , CAR-T cell therapy, chronic heart disease, and COVID-19 is currently being explored. Fig. 2 Hypothetical link between pre-established endothelial cell injury and endothelial vulnerability with mortality after alloSCT. Conditioning therapy, immunosuppressive drugs, and post-transplant complications increase endothelial cell distress. In most patients, the threshold to substantial endothelial dysfunction, disturbed microcirculation/microangiopathy and death will not be trespassed (patient 1). Patient 2 with pre-established endothelial cell injury responds similarly to the additional endothelial strains in the context of alloSCT. However, the threshold will be reached due to a lower area of resilience. Patient 3 without pre-established endothelial injury responds more vigorously to the same endothelial challenges due to a patient-specific endothelial vulnerability. The net effect is again an infringement of the threshold and severe complications/death.

Regarding therapeutic interventions for endothelial damage, defibrotide is currently the only approved drug for the treatment of hepatic SOS/VOD. In a historically controlled multicenter open-label phase-III study [75] a significantly better day +100 survival following alloSCT was observed in the defibrotide arm (38%) compared to controls (25%). Results from a compassionate-use [76] and expanded-access treatment program [77] could further verify the efficacy and safety of defibrotide for the treatment of post-transplant SOS/VOD. For a more detailed review on defibrotide treatment and other recent advances in the therapy of endothelial syndromes see references 78-80. Obviously, the hen-and-egg dilemma-namely whether endothelial defects are cause or consequence of transplantrelated complications-is still not completely solved. However, the evidence outlined in the previous section suggests that a preexisting endothelial aberration is often present, either latent as vulnerability, or as manifest injury (Fig. 1) . If this conclusion is correct, in addition to therapeutic strategies, prophylactic or preemptive measures for endothelium protection at least in those patients who have a biomarker profile suspicious of endothelial vulnerability are highly warranted.

EC-protective drugs that have been explored include statins, ursodeoxycholic acid (UDA), and defibrotide [4, 27, 69, [81] [82] [83] [84] [85] [86] [87] [88] [89] . Regarding statins, preliminary evidence suggests that statin prophylaxis with or without UDA is safe and can reduce the risk of TA-TMA, SOS/VOD, and refractory aGVHD, thereby decreasing NRM (Table 3) . Prophylactic UDA reduced NRM and severe aGVHD in a prospective randomized study [89] . Defibrotide prophylaxis reduced the risk of SOS/VOD and aGVHD in a large pediatric prospective randomized trial with a favorable safety profile [86, 90] . Although conclusive rating of the evidence provided by these studies is hampered by considerable heterogeneity of study design, endpoints, and often small sample size, the bottom-line is that there appear to be some efficacy signals for endothelium protection by all three drugs.

To this end, in 2010 we introduced a statin-based endothelial protection (SEP) combining UDA and pravastatin as institutional routine policy for all patients admitted for alloSCT. This was associated with attenuation of excess NRM in aGVHD patients with biomarkers of endothelial vulnerability, whereas NRM in patients without evidence for endothelial vulnerability remained unchanged (Table 3) . Notably, incidences of SOS/VOD and TA-TMA were also reduced in patients with SEP, as compared to (nonrandomized) controls [27, 69, 71] .

Thus, although randomized studies are missing, the combination of statins and UDA appears to have the capacity to alleviate the complications linked to endothelial vulnerability, but not to repair manifest severe endothelial injury (Table 2) . Therefore, new approaches are necessary for the prevention and treatment of endothelial dysfunction caused by pre-existing endothelial damage. Two obvious principle strategies (which are not mutually exclusive) for achieving this will be detailed in the following: a) reshaping anti-neoplastic and immunosuppressive regimens in order to preserve endothelial integrity; and b) exploring novel agents for endothelial protection or repair for patients with established endothelial dysfunction.

Here, two basic questions have to be addressed: first, where does the pre-existing endothelial lesion derive from -and second, to which extent do conditioning regimens, blood pressure medications, antibiotic, antiviral and antifungal drugs, and immunosuppression add to impairment of physical and functional endothelial integrity in individual patients?

The first question requires a thorough work-up of the endothelial toxicity of agents commonly used in the pre-SCT setting, such as fludarabine, alkylators, and anthracyclines, but also irradiation [91, 92] , but of course also of the contributions of vascular comorbidity unrelated to the neoplastic disease. Regarding the second question, a large variety of drugs frequently employed during or after SCT, such as CNI, sirolimus, calcium channel blockers, and angiotensin-II inhibitors can affect endothelial integrity and may demand patient-based endothelial monitoring [93] [94] [95] [96] . Because of its easy accessibility, also for retrospective analyses, EASIX might be a particularly useful tool for this purpose.

There is a paucity of agents with the capacity of protecting or restoring EC integrity. Given the potential side effects of novel drugs being explored for this purpose, high-risk populations who are most in need of such medications need to be identified. Our experiences with SEP show that endothelial protection may differ for endothelial vulnerability settings and manifest endothelial cell injury. Similarly, the reported benefits of defibrotide and-in children-C5 inhibitors (e.g. Eculizumab [97] ) will have to be analyzed for differential efficacy in patients with different endothelial risk. In adult patients, serious toxicities, e.g. fatal infections with complement C5 inhibitors [98, 99] , strongly discourage using this approach outside of clinical trials.

In addition to searching for novel EC-promoting agents, we should also consider incorporating the established knowledge of cardiovascular medicine for endothelial protection, e.g. by investigating pre-emptive use of statins, beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, acetyl salicylate, or N-acetylcystein [100] amongst others, in patients with evidence for endothelial injury. The EASIX toolkit seems to be particularly practical for classifying endothelial risk for this purpose.

CONCLUSION EC dysfunction syndromes are increasingly recognized as important contributors to mortality and morbidity after alloSCT. Although their pathogenesis is not uniform and the overwhelming functional heterogeneity of EC can channel systemic endothelial disorders into tissue-specific, local microangiopathies, the common final path of EC dysfunction syndromes is a severe and mostly irreversible alteration of EC integrity. There is growing evidence that the manifestation of clinically effective EC disintegration is at least partially driven by distinct pre-existing endothelial defects which can be defined as endothelial vulnerability and endothelial injury, respectively. Whereas endothelial injury represents manifest lesions resulting in permanent endothelial dysfunction, endothelial vulnerability describes latent defects translating into endothelial dysfunction only upon a second hit. These two conditions can be distinguished by biomarker profiling with a prominent role for EASIX. While endothelial vulnerability might potentially be overcome by prophylactic use of endotheliumprotective drugs, such as statins and UDA, effective tools for treating manifest endothelial damage-except for defibrotide in specific settings-are missing. Thus, novel approaches to target endothelial injury and its devastating clinical sequelae appear to be a high-priority goal in order to reduce the risks of allo-SCT. Table 3 . Select studies on intended or incidental prophylaxis with endothelium-protective drugs in allo-SCT. T. Luft et al.

Endothelial function and dysfunction: testing and clinical relevance

Evolving functions of endothelial cells in inflammation

Vascular endothelium and graft-versus-host disease

Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation

Incidence, risk factors, and outcomes of idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation

Endothelial activation and stress index (EASIX) at admission predicts fluid overload in recipients of allogeneic stem cell transplantation

Early Bilirubinemia after allogeneic stem cell transplantation-an endothelial complication

Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease

Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/venoocclusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

Biomarkers for Diagnosis and prognosis of sinusoidal obstruction syndrome after hematopoietic cell transplantation

Endothelium and bone marrow transplantation

Prediction of veno-occlusive disease using biomarkers of endothelial injury

Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications

The release of soluble factors contributing to endothelial activation and damage after hematopoietic stem cell transplantation is not limited to the allogeneic setting and involves several pathogenic mechanisms

Increased plasma level of vascular endothelial glycoprotein thrombomodulin as an early indicator of endothelial damage in bone marrow transplantation

Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy

Transplantation-associated thrombotic microangiopathy: twenty-two years later

Microangiopathy in patients on cyclosporine prophylaxis who developed acute graftversus-host disease after HLA-identical bone marrow transplantation

A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy

Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis

Diagnostic value of hemostatic parameters in bone marrow transplant-associated thrombotic microangiopathy

ST2 and Endothelial Injury as a Link between GVHD and Microangiopathy

Increased levels of tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor (PAI) correlate with tumor necrosis factor alpha (TNF alpha)-release in patients suffering from microangiopathy following allogeneic bone marrow transplantation (BMT)

Plasma von Willebrand Factor Antigen (vWF:AG) and thrombomodulin (TM) levels in adult thrombotic thrombocytopenic purpura/hemolytic uremic syndromes (TTP/HUS) and bone marrow transplant-associated thrombotic microangiopathy (BMT-TM)

Transplant-associated thrombotic microangiopathy is an endothelial complication associated with refractoriness of acute GvHD. Bone Marrow Transplant

Clinicopathological manifestations and treatment of intestinal transplant-associated microangiopathy

Acute Graft-versus-Host Disease -. Biologic process, prevention, and therapy

Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation

Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease

Endothelial vulnerability and endothelial damage are associated with risk of graftversus-host disease and response to steroid treatment

Endothelial-cell injury in cutaneous acute graft-versus-host disease

Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802

Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Serum levels of soluble adhesion molecules in stem cell transplantation-related complications

GVHD after allogeneic haematopoietic SCT for AML: angiogenesis, vascular endothelial growth factor and VEGF receptor expression in the BM

Endothelial damage is aggravated in acute GvHD and could predict its development

Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation

Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation

The immunopathology of upper gastrointestinal acute graft-versus-host disease. Lymphoid cells endothelial Adhes molecules

Endothelial cell markers in bone marrow transplant recipients with and without acute graftversus-host disease

Expression of adhesion molecules in endothelial cells during allogeneic bone marrow transplantation

Endothelial changes in cutaneous graft-versushost disease: a comparison between HLA matched and mismatched recipients of bone marrow transplantation

A novel diagnostic and prognostic biomarker panel for endothelial cell damage-related complications in allogeneic transplantation

ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death

Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation

Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker

Endothelium in health and disease

Single-cell transcriptome atlas of murine endothelial cells

Dynamical systems approach to endothelial heterogeneity

Spatial and temporal dynamics of the endothelium

Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms

Epigenetic Heterogeneity and mitotic heritability prime endothelial cell gene induction

A role of stochastic phenotype switching in generating mosaic endothelial cell heterogeneity

Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation

Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation

Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica

Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction

Angiopoietin-2 levels as a biomarker of cardiovascular risk in patients with hypertension

Angiopoietin-2 as a marker of endothelial activation is a good predictor factor for intensive care unit admission of COVID-19 patients

Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease

Serum nitrite and nitrate levels, NOx, can predict cardiovascular mortality in the elderly in a 3-year follow-up study

Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease

Singlenucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease

Interleukin-18 and outcome after allogeneic stem cell transplantation: a retrospective cohort study

Predicting sinusoidal obstruction syndrome after allogeneic stem cell transplantation with the EASIX biomarker panel

EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis

EASIX and mortality after allogeneic stem cell transplantation

External validation and comparison of multiple prognostic scores in allogeneic hematopoietic stem cell transplantation

EASIX for prediction of survival in lower-risk myelodysplastic syndromes

Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma

Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure

Defibrotide for the treatment of hepatic veno-occlusive disease: final results from the International Compassionate-use Program

Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome

Complement in pathophysiology and treatment of transplantassociated thrombotic microangiopathies

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)

Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation

Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation

The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation

Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease

Recipient immune modulation with atorvastatin for acute graft-versus-host disease prophylaxis after allogeneic transplantation

Defibrotide for sinusoidal obstruction syndrome/veno-occlusive disease prophylaxis in high-risk adult patients: a single-center experience study

Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation

Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation

Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study

Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial

Biomarkers of radiation-induced vascular injury

Detrimental effects of chemotherapeutics and other drugs on the endothelium: a call for endothelial toxicity profiling

Incidence, predictors, and outcomes of veno-occlusive disease/sinusoidal obstruction syndrome after reduced-intensity allogeneic hematopoietic cell transplantation

Calcium channel blockers in restoration of endothelial function: systematic review and meta-analysis of randomized controlled trials

Cyclosporine induces endothelial cell release of complement-activating microparticles

Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling

New approaches in the diagnosis, pathophysiology, and treatment of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy

Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy

Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy

Prophylactic oral NAC reduced poor hematopoietic reconstitution by improving endothelial cells after haploidentical transplantation

Open Access funding enabled and organized by Projekt DEAL.

T.L. and A.R. have nothing to disclose. P.D.: consultancy for AbbVie, AstraZeneca, bluebird bio, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, AstraZeneca, Gilead, Novartis, Riemser, Roche; research support from Riemser.

Correspondence and requests for materials should be addressed to T.L. or P.D.Reprints and permission information is available at http://www.nature.com/ reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.